Filters

Pp-148 manufacturers

Filters

None products found

pp-148

Concentrate for solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Hereditary angioedema (HAE) due to C1 inhibitor deficiency — prophylaxis Clinical stage: Phase 3 Modality: Gene editing therapy (in vivo CRISPR-Cas9 via lipid nanoparticle) Mechanism / Target: Single-dose in vivo knock-out of KLKB1 gene (encoding plasma kallikrein) in hepatocytes; permanently reduces plasma kallikrein, preventing bradykinin generation and HAE attacks Route / form: Single intravenous infusion (LNP delivery to liver) Differentiation: Potentially curative single-dose; permanent reduction vs chronic prophylaxis (lanadelumab, berotralstat); Phase 1/2 showed >90% KLKB1 reduction sustained >2 years
Manufacturer #39179

Pioneering in vivo CRISPR gene editing company targeting genetic diseases at the DNA level. Advances single-administration therapies aimed at permanent correction via lipid nanoparticle delivery. Wholly owned HAE programme independent from its TTR collaboration.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.